Fred Hutchinson spin-out Adaptive Biotechnologies raises $195m for immunotherapy treatments.
Adaptive Biotechnologies, a life sciences firm developing immunotherapy treatments, has raised $195m in its series F round.
Adaptive has now raised $401.5m in venture backing. The latest round was backed by new investors Rock Springs Capital, Tiger Management Corporation, Senator Investment Group, and Matrix Capital. Viking Global, which backed Adaptive’s 2014 $105m venture round, also joined the round, as did fellow existing backers Casdin Capital and Alexandria Real Estate Equities.
The Seattle-based firm is founded on intellectual property from the…
